<?xml version="1.0" encoding="UTF-8"?>
<p class="p">New pharmacological treatments for pain are being developed based on molecular interactions with the endocannabinoid system (
 <xref rid="ref57" ref-type="bibr" class="xref">Woodhams et al., 2017</xref>). Although phytocannabinoids from 
 <italic class="italic">Cannabis sativa</italic> are ligands of the CB1 and CB2 receptors and are approved for certain pain conditions, the blockade of the endocannabinoids metabolism through FAAH and MAGL inhibition may be a new analgesic approach for neuroinflammatory diseases (
 <xref rid="ref12" ref-type="bibr" class="xref">Chiurchiù et al., 2018</xref>). This is the first time that LEO is reported as a potential FAAH/MAGL inhibitor, which could explain at least in part the analgesic effects in this model of neuropathic pain.
</p>
